Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances) · 97.9M shares · +13%/yr ↑ dilution · EDGAR filings ↗
Reference price $2.70 · est. market cap ~$264M — last insider sale, 2026-06-03 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — CRISPR clinical, heavy burn ($166M), funded.
Strengths
- Liquidity — current ratio 3.5 (42nd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Auditor changeRecent 8-K item 4.01 8-K ↗
- Net lossNet loss (net margin -395.0%)
- Cash burnNegative free cash flow (-165.8M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +13%/yr over 4y (dilution, book value/share -97%)
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Insider sellingInsider selling — 6 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, last 6mo) Form 4 ↗
- Revenue declineRevenue -88.6% YoY
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, CITADEL ADVISORS LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-394.9%
Net margin
-395.0%
Return on equity
-586.6%
Return on assets
-85.8%
ROIC
-156.3%
Revenue growth (QoQ)
-88.6%
Debt / equity
2.0×
Current ratio
3.5×
Free cash flow
-$166M
Tangible book value
$27M
Cash & investments
$147M
Cash runway
4q
Stock comp / revenue
24.7%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-03 | Parison Amy | Sell | 464 | $2.70 |
| 2026-06-03 | O'Neill Gilmore Neil | Sell | 15K | $2.70 |
| 2026-06-03 | Burkly Linda | Sell | 731 | $2.70 |
| 2026-03-03 | O'Neill Gilmore Neil | Sell | 5.4K | $2.02 |
| 2026-03-03 | Parison Amy | Sell | 474 | $2.02 |
| 2026-03-03 | Burkly Linda | Sell | 749 | $2.02 |
| 2025-12-03 | Burkly Linda | Sell | 713 | $2.15 |
| 2025-12-03 | O'Neill Gilmore Neil | Sell | 5.6K | $2.15 |
| 2025-12-03 | Parison Amy | Sell | 461 | $2.15 |
| 2025-09-03 | Burkly Linda | Sell | 710 | $2.60 |
| 2025-09-03 | Parison Amy | Sell | 458 | $2.60 |
| 2025-09-03 | O'Neill Gilmore Neil | Sell | 5.6K | $2.60 |
| 2025-08-07 | Parison Amy | Sell | 679 | $2.58 |
| 2025-07-31 | Burkly Linda | Sell | 5.1K | $2.49 |
| 2025-06-03 | Parison Amy | Sell | 446 | $1.72 |
| 2025-06-03 | Burkly Linda | Sell | 726 | $1.72 |
| 2025-06-03 | O'Neill Gilmore Neil | Sell | 15K | $1.72 |
| 2025-03-04 | Lucera Erick | Sell | 4.1K | $1.71 |
| 2025-03-04 | O'Neill Gilmore Neil | Sell | 17K | $1.71 |
| 2025-03-04 | Burkly Linda | Sell | 2.9K | $1.71 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06363760 ↗ | A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia | — | Enrolling By Invitation | 2040-08-01 |
| NCT05444894 ↗ | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) Transfusion Dependent Beta Thalassemia, Hemoglobinopathies | PHASE1/PHASE2 | Active Not Recruiting | 2025-09-01 |
| NCT04853576 ↗ | A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) Sickle Cell Disease, Hemoglobinopathies | PHASE1/PHASE2 | Active Not Recruiting | 2025-08-01 |
| NCT03872479 ↗ | Single Ascending Dose Study in Participants With LCA10 Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies | PHASE1/PHASE2 | Unknown | 2025-05-23 |
| NCT03396042 ↗ | Natural History Study of CEP290-Related Retinal Degeneration Blindness, Leber Congenital Amaurosis 10 | — | Completed | 2022-05-06 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-17 | 0001650664-26-000063 ↗ |
| 8-K | 2026-05-26 | 2026-05-26 | 0001104659-26-066021 ↗ |
| 8-K | 2026-05-26 | 2026-05-26 | 0001104659-26-066317 ↗ |
| 8-K | 2026-05-26 | 2026-05-25 | 0001104659-26-065908 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001650664-26-000049 ↗ |
| 8-K | 2026-05-05 | 2026-05-05 | 0001650664-26-000043 ↗ |
| 10-Q | 2026-05-05 | 2026-03-31 | 0001650664-26-000045 ↗ |
| 8-K | 2026-04-07 | 2026-04-01 | 0001650664-26-000030 ↗ |
| 8-K | 2026-03-27 | 2026-03-26 | 0001650664-26-000027 ↗ |
| 10-K | 2026-03-09 | 2025-12-31 | 0001650664-26-000017 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001650664-26-000013 ↗ |
| 10-Q | 2025-11-10 | 2025-09-30 | 0001650664-25-000156 ↗ |